Press Releases

Press Releases

March 25, 2019
CytomX Therapeutics Announces Transition of Chief Financial Officer
SOUTH SAN FRANCISCO, Calif. , March 25, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today
Additional Formats
March 5, 2019
CytomX to Present at Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif. , March 05, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, announced
Additional Formats
February 27, 2019
CytomX Therapeutics Announces Full-Year 2018 Financial Results
Company to Host a Conference Call Today, February 27, 2019, at 5:00 p.m. EST / 2:00 p.m. PST SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of
Additional Formats
February 26, 2019
CytomX Therapeutics 2019 Research and Development Day Highlights Clinical Data from Lead Programs and the Broad Potential of Probody™ Therapeutic Platform
- CX-2009, a First-in-Class Probody Drug Conjugate Targeting CD166, Demonstrates Encouraging Anti-Cancer Activity in Multiple Tumor Types and Safety in Phase 1 Dose Escalation - - CX-072, A Potentially Differentiated Anti-PD-L1 Agent, Shows Favorable Anti-Cancer Activity in Multiple Tumor Types as
Additional Formats
February 14, 2019
CytomX Therapeutics to Announce Full-Year 2018 Financial Results
-Teleconference Scheduled for February 27, 2019 , at 5:00 p.m. ET - -Company to Host Research and Development Day on February 26, 2019 in New York City - SOUTH SAN FRANCISCO, Calif. , Feb. 14, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused
Additional Formats
February 5, 2019
CytomX Therapeutics Announces Senior Management Appointments
Leadership Team Further Strengthened with Additions of Nick Galli, J.D., as SVP, Chief Business Officer and Leslie Robbins, J.D. as SVP, Intellectual Property SOUTH SAN FRANCISCO, Calif. , Feb. 05, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused
Additional Formats
Displaying 11 - 20 of 21